<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208244</url>
  </required_header>
  <id_info>
    <org_study_id>2017P001427</org_study_id>
    <nct_id>NCT03208244</nct_id>
  </id_info>
  <brief_title>DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant</brief_title>
  <official_title>Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept, single center study for the donation of HCV-positive hearts to&#xD;
      HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of&#xD;
      commercially available DAA therapy to prevent HCV transmission upon transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine if preoperative dosing and sustained administration of&#xD;
      pan-genotypic DAA therapy after cardiac transplantation prevents the transmission of&#xD;
      hepatitis C virus (HCV) infection from an HCV-positive donor heart to an HCV naïve recipient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol transitioned to standard of care, no funding available to support research work&#xD;
  </why_stopped>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Actual">April 5, 2021</completion_date>
  <primary_completion_date type="Actual">April 5, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Received heart transplant from HCV+ donor</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV viral RNA at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (based on number of adverse events and out of range lab values) of DAA therapy in patients undergoing cardiac transplantation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety and tolerablity of commercially available DAA therapy in the cardiac transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating out of range laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>End Stage Heart Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment with HCV Direct Acting Antiviral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clinically prescribed direct acting antiviral</intervention_name>
    <description>HCV treatment for 12 weeks</description>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <other_name>DAA treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient is Age ≥ 18 years&#xD;
&#xD;
          -  Serum ALT within normal limits with no history of liver disease&#xD;
&#xD;
          -  Lack of sensitization (i.e. PRA &lt; 20%) that would be expected to result in a high&#xD;
             likelihood of needing aggressive immunosuppression to treat rejection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sensitization (i.e. PRA &gt;20%)&#xD;
&#xD;
          -  Any liver disease in recipient&#xD;
&#xD;
          -  Albumin &lt; 3g/dl or platelet count &lt; 75 x 103/mL&#xD;
&#xD;
          -  Need for dual organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond L Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masschusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond Chung</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Heart Transplant</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anticipate to share coded data with collaborators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Anticipate data would be available to share within 6 months after the final patient completes the study.</ipd_time_frame>
    <ipd_access_criteria>Coded data would be shared with collaborators who have received IRB approval to use the data and have been approved by the PI for their collaboration.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

